Manifold Bio

📍 Boston, United States👥 41 employees💰 Last funded May 2022
Biotechnology Research🌐 manifold.bio
Website LinkedIn
Manifold Bio is a therapeutics company with an unprecedented advantage in engineering precision biologics. We have developed the world’s first high-throughput in vivo drug design platform, enabled by a novel protein barcoding technology and other innovations at the interface of molecular biology and compute. Our mission is to make the best life-saving drugs available to patients as quickly as possible. We’ve brought together a team with unique expertise in library-guided protein engineering combining DNA synthesis, sequencing, and advanced bioinformatics and machine learning. We’re growing and we’re looking for those who are excited about the potential of our novel approach to engineering biology.
4
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
3
Hong Kong SAR
1
Investor activity2019–2022 · investors recorded per year
201912020220221
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Manifold Bio?
Manifold Bio has 4 investors on record on gritt.io.
When did Manifold Bio last raise funding?
The most recent investment in Manifold Bio recorded on gritt.io was in May 2022.
What industry is Manifold Bio in?
Manifold Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Manifold Bio based?
Manifold Bio is headquartered in Boston, United States.